UNSPSC 51413504: Nimodipine

This classification denotes a calcium channel blocker with the molecular formula C21H26N2O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 57WA9QZ5WH, chemically known as 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester but generally known as nimodipine, which bears US NIH Compound Identifier 4497. European Medicines Agency schedules Nimodipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09297MIG.

UNSPSC 51413504 Nimodipine is a Commodity code covering the procurement of this specific vasodilator medication and closely related advanced life support pharmaceuticals for emergency medical services, hospital systems, and health agency operations. State and local governments buy nimodipine and comparable advanced cardiac and neurological medications through competitive sealed bidding and cooperative purchasing arrangements, typically specifying exact unit quantities, required expiration dating, and delivery timelines to support fire rescue operations, emergency departments, and pharmacy benefit programs. Issuing bodies include city purchasing departments (notably the City of Tampa), state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across state agencies and local government entities. The procurement mix reflects operational drug supply chains rather than individual specialty-pharmaceutical licensing or research applications.

Recent activity spans Florida, Texas, and Minnesota through multistate mechanisms. The City of Tampa issued IFB 26P00188 in April 2026 for advanced life support medications including four specific drug line items (labetalol, epinephrine, adenosine, diltiazem) to supply Tampa Fire Rescue in Hillsborough County, with firm-price bids due April 8, 2026, and an estimated contract value of $40,000 under a Small Local Business Enterprise sheltered-market designation with a 5 percent bid discount. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capability information on direct-to-manufacturer prescription programs and negotiated net pricing models outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with awarded vendors required to supply through three authorized wholesalers and products effective July 1, 2026.